Future challenges in the elimination of bacterial meningitis

Página do item simplificado
dc.contributor.authorBottomley, Matthew J.
dc.contributor.authorSerruto, Davide
dc.contributor.authorSáfadi, Marco Aurelio Palazzi [UNIFESP]
dc.contributor.authorKlugman, Keith P.
dc.contributor.institutionEmory Univ
dc.contributor.institutionNovartis Vaccines & Diagnost Srl
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Witwatersrand
dc.contributor.institutionMRC
dc.date.accessioned2016-01-24T14:27:07Z
dc.date.available2016-01-24T14:27:07Z
dc.date.issued2012-04-30
dc.description.abstractDespite the widespread implementation of several effective vaccines over the past few decades, bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Group B Streptococcus (GBS) still results in unacceptably high levels of human mortality and morbidity. A residual disease burden due to bacterial meningitis is also apparent due to a number of persistent or emerging pathogens, including Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus, Salmonella spp. and Streptococcus suis. Here, we review the current status of bacterial meningitis caused by these pathogens, highlighting how past and present vaccination programs have attempted to counter these pathogens. We discuss how improved pathogen surveillance, implementation of current vaccines, and development of novel vaccines may be expected to further reduce bacterial meningitis and related diseases in the future. (C) 2011 Elsevier B.V. All rights reserved.en
dc.description.affiliationEmory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
dc.description.affiliationNovartis Vaccines & Diagnost Srl, I-53100 Siena, Italy
dc.description.affiliationSanta Casa de São Paulo Sch Med, Dept Pediat, São Paulo, Brazil
dc.description.affiliationUniv Witwatersrand, Natl Inst Communicable Dis, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa
dc.description.affiliationMRC, Johannesburg, South Africa
dc.description.affiliationUnifespUniversidade Federal de São Paulo, EPM, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNovartis Vaccines
dc.format.extentB78-B86
dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2011.12.099
dc.identifier.citationVaccine. Oxford: Elsevier B.V., v. 30, p. B78-B86, 2012.
dc.identifier.doi10.1016/j.vaccine.2011.12.099
dc.identifier.issn0264-410X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/34808
dc.identifier.wosWOS:000305109700014
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofVaccine
dc.rightsAcesso restrito
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectMeningococcusen
dc.subjectStreptococcusen
dc.subjectVaccineen
dc.subjectSurveillanceen
dc.titleFuture challenges in the elimination of bacterial meningitisen
dc.typeArtigo
Arquivos
Coleções
EPM - Artigos